ADO and COVID-19: Based on these findings, it could be postulated that alterations in the CD39/CD73 axis and the loss of CD73 in cytotoxic lymphocytes in COVID-19 could lead to a lower ADO concentration in the ECM, which could contribute to the faster progression and worse outcome of both diabetes and COVID-19.